ProKidney
PROK | NASDAQ
$1.04
$0.00 (-0.48%)
At close: Nov 16, 2026, 4:00 PM ET
$1.07
+$0.03 (+2.88%)
After-hours:
Nov 16, 2026, 7:30 PM ET
-0.48%
(1D)Rating
34.5
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #671/1021 (Top 66%)
Key Statistics
Market Data
Market Cap $349.7M
1D Range
1.01 1.10
52W Range
1.01 2.57
Valuation (TTM)
PE -1.73
PB 1.98
EV/EBITDA -1.19
Valuation (NTM)
Forward PE N/A
Forward PEG 0.04
Price Target $5.00
Cash Flow
FCF Yield -47.6%
SBC Adj. FCF Yield -54.0%
SBC Impact -13.3%
Margins
Gross Margin -12872.9%
Operating Margin -24830.3%
FCF Margin -21495.7%
Growth (CAGR)
Revenue 3Y | 5Y 76.5% |
75.5%
Dil EPS 3Y | 5Y -3.5% |
12.5%
FCF 3Y | 5Y -11.2% |
-10.0%
Returns
ROA -49.1%
ROE 10.8%
ROIC -104.3%
Financial Health
Net Cash
$139.72M
Current Ratio 5.04
Interest Coverage -10,690.83
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship product is Renal Autologous Cell Ther...
Sector Healthcare
Industry Biotechnology
Employees 231
IPO Date Jun 30, 2021
Website www.prokidney.com
Fiscal Year January - December
Latest News
No news articles available yet.
Earnings
Latest Earnings
Nov 12, 2026
EPS
-$0.17
Miss -6.39%
YoY:
-41.67% REV
$174K
Beat +39.65%
YoY:
-19.82%Next Earnings
Mar 17, 2027
EPS Est
Pro
Rev Est
Pro
Analyst Summary
# of Analysts
2
Consensus
Buy
Price Target
$5.00
Upside
+380.77%
Buy (2)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove PROK